New · CUSIP 74006W207 · who reports it, how much, and how much it matters to them
42 of the 720 hedge fund managers we track reported shares of Praxis Precision Medicines, Inc. (Nasdaq: PRAX) on Form 13F for 30 June 2026. Between them they reported USD 2.3bn. The largest position belongs to Perceptive Advisors, at USD 682m. The manager with the most riding on it is Acuta Capital Partners, where it is 19.3% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Perceptive Advisors6 funds on PPLI.com | USD 682m | 10.2% |
| 2 | Baker Bros. Advisors2 funds on PPLI.com | USD 587m | 2.9% |
| 3 | Adage Capital Management1 fund on PPLI.com | USD 340m | 0.5% |
| 4 | Cormorant Asset Management1 fund on PPLI.com | USD 214m | 11.0% |
| 5 | Polar Capital LLP26 funds on PPLI.com | USD 93m | 0.2% |
| 6 | Logos Global Management1 fund on PPLI.com | USD 87m | 3.7% |
| 7 | Orbimed Advisors1 fund on PPLI.com | USD 77m | 1.4% |
| 8 | Marshall Wace LLP84 funds on PPLI.com | USD 46m | 0.0% |
| 9 | Acuta Capital Partners2 funds on PPLI.com | USD 28m | 19.3% |
| 10 | Boxer Capital Management1 fund on PPLI.com | USD 16m | 1.2% |
| 11 | Arrowmark Colorado Holdings24 funds on PPLI.com | USD 15m | 0.6% |
| 12 | Squarepoint Ops7 funds on PPLI.com | USD 14m | 0.0% |
| 13 | PFM Health Sciences3 funds on PPLI.com | USD 13m | 1.1% |
| 14 | Burkehill Global Management5 funds on PPLI.com | USD 12m | 0.4% |
| 15 | HighVista Strategies27 funds on PPLI.com | USD 10m | 2.3% |
| 16 | Exome Asset Management2 funds on PPLI.com | USD 9.1m | 5.6% |
| 17 | Capital Fund Management S.A.12 funds on PPLI.com | USD 9.1m | 0.0% |
| 18 | Two Sigma Investments35 funds on PPLI.com | USD 6.3m | 0.0% |
| 19 | Boothbay Fund Management2 funds on PPLI.com | USD 6m | 0.1% |
| 20 | J. Goldman & Co.1 fund on PPLI.com | USD 5.4m | 0.1% |
| 21 | Atika Capital Management3 funds on PPLI.com | USD 4.3m | 0.3% |
| 22 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 3.5m | 0.0% |
| 23 | Cinctive Capital Management5 funds on PPLI.com | USD 2.8m | 0.1% |
| 24 | Atom Investors1 fund on PPLI.com | USD 2.6m | 0.2% |
| 25 | Citadel Advisors32 funds on PPLI.com | USD 2.5m | 0.0% |
| 26 | Sofinnova Investments1 fund on PPLI.com | USD 2.2m | 0.1% |
| 27 | D. E. Shaw & Co.15 funds on PPLI.com | USD 1.7m | 0.0% |
| 28 | Lion Point Capital1 fund on PPLI.com | USD 1.5m | 7.1% |
| 29 | Fora Capital1 fund on PPLI.com | USD 1.4m | 0.1% |
| 30 | Scientech Research2 funds on PPLI.com | USD 1.1m | 0.9% |
| 31 | The Quarry1 fund on PPLI.com | USD 922,000 | 0.1% |
| 32 | Artia Global Partners1 fund on PPLI.com | USD 837,000 | 0.2% |
| 33 | Tudor Investment Corporation10 funds on PPLI.com | USD 731,000 | 0.0% |
| 34 | Jain Global1 fund on PPLI.com | USD 726,000 | 0.0% |
| 35 | Wexford Capital8 funds on PPLI.com | USD 670,000 | 0.1% |
| 36 | Magnetar Financial93 funds on PPLI.com | USD 640,000 | 0.0% |
| 37 | Balyasny Asset Management25 funds on PPLI.com | USD 629,000 | 0.0% |
| 38 | Brevan Howard Capital Management39 funds on PPLI.com | USD 495,000 | 0.0% |
| 39 | Dark Forest Capital Management2 funds on PPLI.com | USD 446,000 | 0.0% |
| 40 | Millennium Management6 funds on PPLI.com | USD 333,000 | 0.0% |
| 41 | CIBC Asset Management69 funds on PPLI.com | USD 289,000 | 0.0% |
| 42 | Bayforest Capital1 fund on PPLI.com | USD 19,418 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Acuta Capital Partners | USD 28m | 19.3% |
| 2 | Cormorant Asset Management | USD 214m | 11.0% |
| 3 | Perceptive Advisors | USD 682m | 10.2% |
| 4 | Lion Point Capital | USD 1.5m | 7.1% |
| 5 | Exome Asset Management | USD 9.1m | 5.6% |
| 6 | Logos Global Management | USD 87m | 3.7% |
| 7 | Baker Bros. Advisors | USD 587m | 2.9% |
| 8 | HighVista Strategies | USD 10m | 2.3% |
| 9 | Orbimed Advisors | USD 77m | 1.4% |
| 10 | Boxer Capital Management | USD 16m | 1.2% |
Praxis Precision Medicines, Inc. trades under the symbol PRAX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 74006W207.
42 of the 720 hedge fund managers PPLI.com tracks reported Praxis Precision Medicines, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Perceptive Advisors (USD 682m), Baker Bros. Advisors (USD 587m), Adage Capital Management (USD 340m), Cormorant Asset Management (USD 214m) and Polar Capital LLP (USD 93m).
42 managers in our coverage reported it, and between them they run 590 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Acuta Capital Partners, where the position was 19.3% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Praxis Precision Medicines, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.